Gleostine (Lomustine) for Lymphoma

Overview
Gleostine is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat Hodgkin lymphoma that has progressed after initial therapy. Gleostine is often combined with a chemotherapy regimen. Gleostine is also known by its drug name, lomustine. Lomustine was previously marketed as CeeNU.

Gleostine is an anticancer drug and a member of a class of drugs called alkylating agents. Gleostine is believed to work by preventing the production of DNA in cells, thereby blocking cell division.

How do I take it?
Gleostine is taken orally once every six weeks.

Gleostine is available as a capsule.

Side effects
The FDA-approved label for Gleostine lists common side effects including nausea, vomiting, hair loss, and mouth sores. Delayed myelosuppression – decreased bone marrow activity that causes a dangerous drop in blood cell counts – is a common and dangerous side effect of taking Gleostine.

Rare but serious side effects listed for Gleostine include lung and liver damage, kidney failure, fetal harm, a risk for fatal overdose, and an increased risk for developing other cancers such as leukemia and myelodysplasia.

For more details about this treatment, visit:

Gleostine — NextSource Biotechnology
http://gleostine.com